Viva Biotech Holdings (SEHK: 1873)
Health Care · Life Sciences Tools & Services · CN
HK$1.59
+0.63% today · -35.9% 1Y
Viva Biotech Holdings (SEHK: 1873) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $420.77M and employs 2,169 people.
Over the last twelve months the share price has lost 35.9%, trading between 1.04 and 3.27.
Tweenvest scores Viva Biotech Holdings across four factors: quality 63/100, value 65/100, growth 3/100. Its strongest factor is value.
1873 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $420.77M
- Revenue (TTM)
- $247.26M
- P/E
- 15.88
- EPS
- 0.09
- Dividend yield
- —
- Beta (5Y)
- 1.38
- 52-week high
- HK$3.27
- 52-week low
- HK$1.04
- Avg volume (3M)
- —
- Shares outstanding
- 2.07B
- Employees
- 2,169
- Next earnings
- —
About Viva Biotech Holdings
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
- ISIN
- KYG9390W1015
- Founded
- 2008
- Listed since
- May 9, 2019
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $629.27 | +0.27% |
| Danaher CorporationNYSE: DHR | $153.85B | $218.85 | +1.36% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF592.20 | +1.09% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $159.00 | +1.73% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.82 | +1.47% |
| Waters CorporationNYSE: WAT | $40.35B | $410.70 | +1.49% |
Figures last refreshed Aug 18, 2026.